Placeholder Image

字幕列表 影片播放

  • The BBSRC has three main themes to a Strategic Plan for Research. One of these is the basic

  • bioscience underpinning human health. That is where Babraham science is focused. Unless

  • we understand the basic bioscience which underpins human health then we will not be in a position

  • to be able to understand what goes wrong in human disease.

  • So Babraham's research is split into three major themes. Firstly, there is the cellular

  • signalling grouping, secondly the immunology grouping and thirdly epigenetics and chromatin.

  • In the signalling programme we are understanding how acute responsiveness occurs, for instance,

  • in the way in which a body deals with infections. That leads into the immunology where understanding

  • how the immune system develops, how it changes during aging for example, whereas within epigenetics

  • and chromatin we are looking firstly at developing organisms and secondly at how the body has

  • adapted to changes in its environment.

  • Epigenetic modification or changes to the DNA and the chromatin in the nucleus which

  • make the genome experience the environment in a particular way and talk to the genome

  • and make it function, make the organism function in a particular way. Imagine that there is

  • about 200 or 300 different cells in the human body that all have their own unique epigenetic

  • information and epigenome, as we call it, which is uniquely characteristic of each cell

  • type. So there is liver cells which have a particular epigenome, there is brain cells

  • which have another type of epigenome and the epigenome, in essence, instructs the genome

  • to only use a particular subset of all the genes that it has in order to confer identity,

  • be it a liver cell, be it a brain cell on the particular cells in the body.

  • For example, we know that colleagues here at the Institute have discovered that that

  • a particular class of genes that are epigenetically regulated controls the amount of fat that

  • the body acquires during development and after birth and later on and so it is possible that

  • this type of epigenetic regulation underlies the develop of obesity for example later in

  • life and perhaps alter diabetes.

  • Dr Michael Wakelam, Director of Babraham Institute Babraham has a number of technologies which

  • facilitates it work. Firstly, there are mass spectrometry methodologies which allow us

  • here not to just look at proteins as in many places but also at lipids which are critically

  • important in signalling processes in cells. Secondly, we have specialised systems such

  • as phosphorescence activated cell sorters...

  • ...which allow us to isolate particular populations of cells, for instance, immune cells for study.

  • Babraham is at the forefront of epigenetics research in Europe. It is one of the largest

  • centres that carries out this type of research and the technology we have been able to develop

  • here and build up through investments by BBSRC, MRC and also the University of Cambridge has

  • really put us at the forefront of this kind of epigenomics field worldwide.

  • Our imagine facility has a number of microscopes. Particularly the confocal microscopes can

  • be used to identify the localisation within a cell of various proteins on genes. This

  • technology has been developed further recently to allow the examination of these cells under

  • live conditions. This means we can look at the movement of proteins for instance within

  • a cell when it has been stimulated. A good example of this is a neutrophil which is responding

  • to an infection.

  • We can look at the movement of signalling proteins within these cells in response to

  • the infection and see how that changes in the presence of various pharmacological inhibitors,

  • therefore, allowing us to investigate the disease processes.

  • Links with companies is extremely important for Babraham science. That is because, whilst

  • the research has its own intrinsic importance, at the end of the day it has to have a benefit

  • for society.

  • We have a number of links with the companies in our incubators on site of which there are

  • 32 at present. Some of these are spin-outs from Babraham science, others have chosen

  • to locate here where they can, amongst other things, interact with and collaborate with

  • the Babraham scientists.

  • Crescendo is a new biotech company established at the beginning of 2009 aiming to make new

  • antibody based therapeutics.

  • The advantages of antibodies as therapeutic agents are that they are highly specific and

  • they don't have the unpredictable side effects of small molecule drugs. At Crescendo we are

  • trying to develop antibody based fragment therapeutics...

  • ...which have those advantages but also the advantages of small molecules, in other words,

  • topical delivery, no need for injection.

  • The science that is the basis for Crescendo has been occurring over about 10 years here

  • at Babraham and it has been pioneered by Drs Marianne Brugerman and Mike Towsick. The advantages

  • of being based at Babraham are that we are living a very rich scientific environment

  • and we are constantly tapping into the scientific expertise of the Institute. There are about

  • 20 or 30 other companies based at Babraham and that makes it an exciting environment

  • to be in.

The BBSRC has three main themes to a Strategic Plan for Research. One of these is the basic

字幕與單字

單字即點即查 點擊單字可以查詢單字解釋

B1 中級 美國腔

現代生物醫學。巴卜拉漢姆研究所 (Modern biomedicine: The Babraham Institute)

  • 73 12
    楊子儀 發佈於 2021 年 01 月 14 日
影片單字